A new targeted cancer drug, DB-1310, is showing early signs of effectiveness in patients with advanced solid tumors that have not responded to standard treatments, particularly those with EGFR-mutant non-small cell lung cancer, according to results from an international clinical trial led by Aaron Lisberg at the UCLA Health Jonsson Comprehensive Cancer Center.
A lab-designed molecule developed and extensively studied by scientists with Virginia Tech’s Fralin Biomedical Research Institute at VTC could represent a breakthrough in slowing tumor recurrence in glioblastoma, an aggressive and deadly form of brain cancer.
A dysfunction in muscle blood vessels could be to blame for the weak muscles and weight loss that most cancer patients experience, according to a new study from University of Illinois Chicago researchers.
A recent OncoHost study provides insight in understanding resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer. Through a comprehensive bioinformatic analysis of pretreatment plasma proteomic profiles from 272 NSCLC patients, researchers identified key biological processes associated with resistance and revealed therapeutic targets that could inform future precision treatment strategies.
Alcohol is a leading preventable cause of cancer, but public awareness of the connection remains strikingly low in the U.S., with just 40% of American adults recognizing alcohol as a cancer risk, according to a new study from the University of Texas MD Anderson Cancer Center.
Investigator-initiated EFTISARC-NEO phase II trial evaluating eftilagimod alfa (efti) with radiotherapy plus Keytruda (pembrolizumab) in the neoadjuvant setting for resectable soft tissue sarcoma has met its primary endpoint.
Breathing in wildfire pollution may make it harder for people with lung cancer to survive, according to a new study from UC Davis Comprehensive Cancer Center researchers.
Researchers from the University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was predictive of survival outcomes for patients with advanced KRAS G12C-mutated non-small cell lung cancer, following treatment with the KRAS targeted therapy, sotorasib.
New research out of VCU Massey Comprehensive Cancer Center is the first to suggest that a tumor-driving gene known as AEG-1 actively regulates the inflammation responsible for causing chemotherapy-induced peripheral neuropathy, a common and painful side effect of cancer treatment. Eliminating the function of this gene using targeted therapies could become a critical strategy for managing a debilitating side effect experienced by many cancer patients.
An artificial intelligence technique for detecting DNA fragments shed by tumors and circulating in a patient’s blood, developed by Johns Hopkins Kimmel Cancer Center investigators, could help clinicians more quickly identify and determine if pancreatic cancer therapies are working.
